Abstract
The link between cancer and venous thromboembolism is well known, with an annual incidence rate of venous thromboembolism between 0.5% and 20% depending on the primary site and background risk factors. Current guidelines suggest treatment with low-molecular-weight heparin over oral vitamin K antagonists. However, data regarding the management of recurrent venous thromboembolism when the patient is under treatment with anticoagulants are sparse. In this article we present a patient with multiple thromboembolic events in unusual sites despite anticoagulant treatment and we discuss the management options.
MeSH terms
-
Adenocarcinoma / secondary*
-
Carcinoma, Non-Small-Cell Lung / secondary*
-
Fatal Outcome
-
Fibrinolytic Agents / therapeutic use*
-
Heparin, Low-Molecular-Weight / therapeutic use*
-
Humans
-
Jugular Veins
-
Lung Neoplasms* / complications
-
Male
-
Mesenteric Artery, Superior
-
Mesenteric Vascular Occlusion / etiology
-
Mesenteric Vascular Occlusion / prevention & control
-
Middle Aged
-
Secondary Prevention
-
Subclavian Vein
-
Thrombosis / etiology
-
Thrombosis / prevention & control*
-
Tinzaparin
-
Treatment Failure
-
Venous Thromboembolism / etiology
-
Venous Thromboembolism / prevention & control*
-
Venous Thrombosis / etiology
-
Venous Thrombosis / prevention & control
Substances
-
Fibrinolytic Agents
-
Heparin, Low-Molecular-Weight
-
Tinzaparin